Lenalidomide and its role in the management of multiple myeloma (Q37183439)

18 August 2017

1 reference

title

Lenalidomide and its role in the management of multiple myeloma (English)

1 reference

18 August 2017

Alessandra Larocca

3

0 references

Federica Cavallo

object named as

Federica Cavallo

2

0 references

Pellegrino Musto

object named as

Pellegrino Musto

5

0 references

Antonio Palumbo

7

object named as

Antonio Palumbo

1 reference

18 August 2017

Patrizia Falco

1

1 reference

PubMed ID

18533796

18 August 2017

Anna Marina Liberati

4

1 reference

PubMed ID

18533796

18 August 2017

Mario Boccadoro

6

1 reference

18 August 2017

1 June 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

865-874

1 reference

18 August 2017

6

1 reference

A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Lenalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

The evolving role of lenalidomide in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Multiple Myeloma. Advances in disease biology: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Biology of umbilical cord blood progenitors in bone marrow niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Risk of thrombosis with lenalidomide and its prevention with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.865

21 January 2018

Identifiers

DOI

10.1586/14737140.8.6.865

1 reference

18 August 2017

1 reference

PubMed ID

18533796